Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Kisspeptin
Upstream regulator of reproductive axis (GnRH/LH/FSH). FDA-flagged for compounding concerns.
Tier Bmedium risk
02· Subject
Melanotan II
Unlicensed broad melanocortin agonist with pigmentation and sexual side-effect profiles. Highest compliance risk.
Tier Chigh risk
01 · At a glance
| Decision factor | Kisspeptin | Melanotan II | PT-141 |
|---|---|---|---|
| Primary fit | sexual health & libido research where you want a clear starting point | skin & hair and sexual health & libido comparisons | sexual health & libido research where you want a clear starting point |
| Evidence | Tier B | Tier C | Tier A |
| Risk | medium | high | low |
| Experience level | advanced | advanced | advanced |
| Budget tier | premium | budget | premium |
| Administration route | intravenous, subcutaneous | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Kisspeptin | Melanotan II | PT-141 |
|---|---|---|---|
| Goal fit | Sexual Health & Libido | Skin & Hair, Sexual Health & Libido | Sexual Health & Libido |
| What users compare it for | LH/FSH axis stimulation; fertility research applications. | Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product. | Improved sexual desire in premenopausal women with acquired generalized HSDD. |
| Onset timeline | Acute LH response within ~45 minutes; fertility endpoints context-specific. | Pigmentation changes can occur quickly; adverse events can be acute. | Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Kisspeptin | Melanotan II | PT-141 |
|---|---|---|---|
| Adverse effects | FDA: limited safety data, immunogenicity concerns for compounding. | FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns. | Nausea, flushing, injection site reactions, headache, vomiting. BP elevation. |
| Contraindications | No formal label; high endocrine interaction potential. | High risk across the board; unlicensed and unapproved. | Uncontrolled hypertension, known cardiovascular disease. Avoid co-use with oral naltrexone-containing products. |
| Interaction notes | High endocrine interaction potential with GnRH analogues and gonadotropins. Do not provide stacking guidance. | Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures. | Slowed gastric emptying impacts absorption of concomitant oral meds. Clinically meaningful interaction with oral naltrexone. |
| Regulatory status | Not approved | Not approved | Prescription-approved |
| FDA flag | FDA compounding caution | FDA compounding caution | No current flag noted |
| WADA status | WADA S2 | Status unclear | Not listed |
04 · Age & monitoring
| Decision factor | Kisspeptin | Melanotan II | PT-141 |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | 25-34, 35-44, 45-54, 55-64 |
| Life-stage note | Not yet documented | Not yet documented | Adult sexual-health use case with strongest fit before later-life cardiovascular burden becomes a larger concern. |
| Monitoring burden | Not specified | Not specified | medium |
| Follow-up cadence | Not yet documented | Not yet documented | Review tolerance early and reassess if use becomes frequent. |
05 · Cost & sourcing
| Decision factor | Kisspeptin | Melanotan II | PT-141 |
|---|---|---|---|
| Typical cycle cost | No reliable estimate yet | $80.00 | €27.29 |
| Estimated monthly cost | No reliable estimate yet | $53.33 | €27.29 |
| Cost confidence | No estimate | High confidence | High confidence |
06 · Before you buy
| Decision factor | Kisspeptin | Melanotan II | PT-141 |
|---|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Better as a standalone decision | Usually stack-friendly | Better as a standalone decision |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.